Orphazyme A/S banner

Orphazyme A/S
CSE:ORPHA

Watchlist Manager
Orphazyme A/S Logo
Orphazyme A/S
CSE:ORPHA
Watchlist
Price: 850 DKK 1.19%
Market Cap: kr34m

Orphazyme A/S
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Orphazyme A/S
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Orphazyme A/S
CSE:ORPHA
Other Items
-kr6.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Other Items
-kr5.6B
CAGR 3-Years
-153%
CAGR 5-Years
-78%
CAGR 10-Years
-60%
Zealand Pharma A/S
CSE:ZEAL
Other Items
-kr2.2B
CAGR 3-Years
N/A
CAGR 5-Years
-66%
CAGR 10-Years
N/A
Galecto Inc
NASDAQ:GLTO
Other Items
$11.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Other Items
-kr48.5m
CAGR 3-Years
56%
CAGR 5-Years
56%
CAGR 10-Years
23%
No Stocks Found

Orphazyme A/S
Glance View

Market Cap
34m DKK
Industry
Biotechnology

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.

ORPHA Intrinsic Value
Not Available

See Also

What is Orphazyme A/S's Other Items?
Other Items
-6.9m DKK

Based on the financial report for Dec 31, 2023, Orphazyme A/S's Other Items amounts to -6.9m DKK.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett